Meet PSI at CTAD 2026!
PSI CRO, a global contract research organization founded in 1995 and operating across 58 countries, will attend CTAD 2026 to discuss the operational realities sponsors face as pivotal Alzheimer’s disease programs become more data-intensive and globally distributed.
As AD clinical development shifts toward biomarker-driven patient selection, AI-enabled trial operations, and advanced endpoint strategies, CTAD 2026 unites scientific and operational leaders tackling the most pressing challenges in neurodegenerative research. Today’s sponsors must identify the right patients earlier, manage imaging-intensive safety requirements such as ARIAs, and implement complex protocols, while still maintaining enrollment timelines and endpoint integrity.
PSI brings more than 25 years of CNS trial experience across complex Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, stroke, and spasticity programs. PSI’s neurology teams combine therapeutic expertise with operational execution strategies that help sponsors maintain control over enrollment, data quality, and delivery timelines in long-duration neurodegenerative studies.
Attending team members:
- Wendy Bond
Medical Monitor, Medical Affairs - Adam Couture
Associate Director, Business Development
Related resources:
Blog: Blood biomarkers, combination therapies, and AI co-scientists: AD/PD 2026 signals for sponsors
Webinar: Agentic AI in clinical trials: Where we are now and where we are going
White Paper: The operational reality of agentic AI in phase 2-3 trials
